Amgen (AMGN) PT Moves To $216 At Citi On Neulasta and Sensipar

Citi analyst, Robyn Karnauskas, reiterated her Neutral rating on shares of Amgen (NASDAQ: AMGN) but raised her price target to $216 after fine tuning her model and determining that guidance for FY19 could move to $22.6B-$23.5B (compared to FY2018 guidance of $21.8-$22.8B provided at 4Q17 earnings).

The analyst stated "We believe major swing factors to this revenue range will be biosimilar competition around Neulasta and Sensipar generic entry. In our view, Neulasta US sales could be ~$3.0B - $3.4B and Sensipar could be $1.4B - $1.6B". The PT of $216 is up from $210.

For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.

Shares of Amgen closed at $203.88 yesterday.

You May Also Be Interested In

• Amgen (AMGN) PT Raised to $400 at Cantor Fitzgerald on Higher Sales Estimates
• Sino Biopharmaceutical Ltd. (1177:HK) (SBMFF) PT Lowered to HK$8 at Macquarie
• Hengan International Group (1044:HK) (HEGIY) PT Lowered to HK$24.70 at Macquarie